Oncologia
Covid-19: estudo mostra que a efetividade vacinal diminui mais rapidamente em pacientes oncológicos.
30 Mai, 2022 | 13:13hComentário: Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds – The BMJ
Diretrizes atuais para o manejo cirúrgico de cânceres colorretais hereditários.
30 Mai, 2022 | 13:10hEstudo randomizado | Efeito da radioterapia em posição supina vs. prona sobre os efeitos cutâneos tóxicos agudos em mulheres com mamas densas.
30 Mai, 2022 | 13:05hEffect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial – JAMA Oncology (gratuito por tempo limitado)
Editorial: Prone Whole-Breast Radiotherapy—Better Than Supine? (gratuito por tempo limitado)
Comentário no Twitter
Adjuvant breast radiotherapy in the prone position decreases acute skin toxicity in women with large breast size, as demonstrated by this multicenter randomized clinical trial. https://t.co/6Emr2Hy5KH #BCSM #RadOnc
— JAMA Oncology (@JAMAOnc) May 26, 2022
Estudo de coorte | Idade de início da endoscopia de trato gastrintestinal baixo e risco de câncer colorretal.
30 Mai, 2022 | 12:55hAge at Initiation of Lower Gastrointestinal Endoscopy and Colorectal Cancer Risk Among US Women – JAMA Oncology (link para o resumo – $ para o texto completo)
Comentários:
Conteúdos relacionados:
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
ACG Clinical Guidelines: Colorectal Cancer Screening 2021 – The American Journal of Gastroenterology
Screening and prevention of colorectal cancer – The BMJ
Current and future colorectal cancer screening strategies – Nature Reviews Gastroenterology & Hepatology (se o acesso a este link for pago, tente este em PMC)
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study – The Lancet Gastroenterology & Hepatology (link para o resumo – $ para o texto completo)
Comentário no Twitter
Initiation of an endoscopy before age 50 was associated with lower risk of colorectal cancer incidence & young-onset cancer. These findings support recent guidelines that recommend initiating colorectal cancer screening before age 50. https://t.co/T85cIS5AIS #CRCSM #GICSM
— JAMA Oncology (@JAMAOnc) May 5, 2022
Estudo randomizado | Eficácia e segurança do uso de pazopanibe com TRC105 vs. pazopanibe isolado para tratamento de pacientes com angiossarcoma avançado.
30 Mai, 2022 | 12:45hComentários:
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post
Comentários no Twitter
A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx
— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022
First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2
— JAMA Oncology (@JAMAOnc) March 31, 2022
Estudo randomizado | Tiragolumabe com atezolizumabe vs. placebo com atezolizumabe como tratamento de primeira linha para câncer de pulmão de não pequenas células com expressão de PD-L1.
30 Mai, 2022 | 12:44hTiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário: First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC – Medicine Matters
Estudo randomizado | Adebrelimabe ou placebo com carboplatina e etoposídeo como tratamento de primeira linha para câncer de pulmão de pequenas células em estágio extenso.
30 Mai, 2022 | 12:40hAdebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Navegando pela toxicidade financeira em pacientes com câncer: uma abordagem de tratamento multidisciplinar.
27 Mai, 2022 | 13:37hConteúdos relacionados:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
Posicionamento científico | Implementação de teste para BRCA preventivo e preditivo em pacientes com cânceres de mama, ovário, pâncreas e próstata.
27 Mai, 2022 | 13:29hEstudo randomizado fase 1/2 | Segurança e eficácia do inibidor mTOR (vistusertibe) combinado com anastrazol em pacientes com câncer endometrial metastático ou positivo para receptor hormonal.
27 Mai, 2022 | 13:22hSafety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
Endocrine therapy is used in clinical practice in the management of relapsed or advanced HR + endometrial cancer. Anastrozole + vistusertib demonstrated clinically significant improvement with manageable adverse events, encouraging further research https://t.co/hHDtloSdNs #GynCSM
— JAMA Oncology (@JAMAOnc) May 12, 2022